Cetyl myristoleate — abbreviated CM or CMO, and sold in branded form as CM8® in Flexcin and FlexPet — is the cetyl ester of myristoleic acid. In plain terms, it's an oil-like fatty acid compound, and that lipid nature is the whole point: it belongs to the same broad family as the substances the body uses to keep joints cushioned and moving smoothly.
The chemistry, without the headache
Strip away the jargon and there are three things worth knowing.
First, it's a fatty acid, not a sugar. Glucosamine and chondroitin — the ingredients in most joint formulas — are sugar-based building blocks. Cetyl myristoleate sits in a different category entirely: it's a lipid, formed by joining myristoleic acid to cetyl alcohol.
Second, it's monounsaturated. Myristoleic acid is a 14-carbon fatty acid with a single double bond — one "kink" in an otherwise straight chain. That single point of unsaturation is what makes it monounsaturated, structurally akin to the monounsaturated oils people already know, like olive oil. (Technically the two differ in where that double bond sits — myristoleic acid is an omega-5, olive oil's oleic acid an omega-9 — but the monounsaturated kinship is real.)
Third, it barely occurs in people. Cetyl myristoleate turns up naturally in the fats of a handful of animals — certain mice, beavers, sperm whales, and in trace amounts in dairy butterfat — but isn't something the human body makes in meaningful quantity. Commercial cetyl myristoleate is produced by esterifying myristoleic acid with cetyl alcohol, so no animals are involved.
An accidental discovery at the NIH
Cetyl myristoleate has an unusually good origin story. It was first isolated by Dr. Harry W. Diehl, a research chemist who spent decades at the U.S. National Institutes of Health, in the Laboratory of Chemistry at what was then the National Institute of Arthritis, Metabolic, and Digestive Diseases.
Diehl's work involved inducing arthritis in lab mice so anti-inflammatory compounds could be tested. The trouble was that one group — Swiss albino mice — stubbornly refused to develop it. Curious why, he investigated, and traced the resistance to a compound the mice carried: cetyl myristoleate, which he isolated and identified by thin-layer chromatography. The compound hadn't appeared in the chemical literature before his work.
He went on to receive U.S. patents for it — including one for the compound itself in 1977 and a later method patent in 1996 — and the ingredient reached the consumer market as a dietary supplement in the early 1990s. (Accounts of the exact discovery year vary across retellings, which is worth keeping in mind whenever you read about it.)
How it's thought to work
This is where honesty matters. The proposed role of cetyl myristoleate is as a kind of joint lubricant — a lipid that helps support the smooth, cushioned movement of joint surfaces and the comfort that goes with it. Researchers have also explored whether it influences the membranes of cells involved in the joint environment.
But the precise mechanisms are still not fully established, and the body of human research is smaller than for long-studied ingredients. Anyone who tells you the mechanism is settled science is overselling it. What can be said fairly:
- It is studied specifically in the context of joint comfort and range of motion, not general nutrition.
- It is used both on its own and alongside familiar ingredients like MSM, collagen, and glucosamine in combination formulas.
- The strength of the evidence, and what the key studies actually measured, is worth reading before forming an opinion.
We lay that out plainly on the research summary — including the limits of the studies, not just the headlines.